Each assay in the OncoFirm™ pipeline runs on the same platform: our Proprietary Fluorescent Lateral Flow Antigen Technology, which delivers quantitative results in minutes from a small sample, read on a compact fluorescent reader. Our lead program is CEA for colorectal cancer monitoring, followed by PSA. Hepatitis B and C panels are in development. Infectious disease, inflammation and cardiac markers are planned next, with prenatal, viral and tropical disease assays further out. Every page below explains why the marker matters, how the test works and where it stands on our roadmap. We welcome clinical, research and commercial partners at every stage.
Planned OncoFirm influenza A/B fluorescent antigen assay, instrument-read and logged, designed to run with COVID-19 and RSV tests. Not for sale.
Planned OncoFirm quantitative CRP fluorescent assay for point-of-care inflammation and antibiotic stewardship decisions. Not for sale.